🚀 VC round data is live in beta, check it out!
Stratec Valuation Multiples
Discover revenue and EBITDA valuation multiples for Stratec and similar public comparables like 908 Devices, Orchestra BioMed, Ascom, Senseonics Holdings and more.
Stratec Overview
About Stratec
Stratec SE designs and manufactures automated analyzer systems for laboratory data management and solutions for molecular diagnostic sample preparation and stabilization. Its business segments are Instrumentation, Diatron and Smart Consumables. Its Instrumentation segment is engaged in designing and manufacturing automated analyzer systems for clinical diagnostics and biotechnology customers. The Diatron segment comprises the business with systems, system components, consumables, and tests in the low throughput hematology and clinical chemistry segment. Its Smart Consumables segment is engaged in developing and selling scientific materials, such as nucleic acid purification. The company generates maximum revenue from the Instrumentation segment.
Founded
1979
HQ
Employees
1.4K
Website
Financials (LTM)
EV
$361M
Stratec Financials
Stratec reported last 12-month revenue of $304M and EBITDA of $48M.
In the same LTM period, Stratec generated $83M in gross profit, $48M in EBITDA, and $16M in net income.
Revenue (LTM)
Stratec P&L
In the most recent fiscal year, Stratec reported revenue of $303M and EBITDA of $56M.
Stratec expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $304M | XXX | $303M | XXX | XXX | XXX |
| Gross Profit | $83M | XXX | $90M | XXX | XXX | XXX |
| Gross Margin | 27% | XXX | 30% | XXX | XXX | XXX |
| EBITDA | $48M | XXX | $56M | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 18% | XXX | XXX | XXX |
| EBIT Margin | 9% | XXX | 11% | XXX | XXX | XXX |
| Net Profit | $16M | XXX | $19M | XXX | XXX | XXX |
| Net Margin | 5% | XXX | 6% | XXX | XXX | XXX |
| Net Debt | — | — | $80M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Stratec Stock Performance
Stratec has current market cap of $265M, and enterprise value of $361M.
Market Cap Evolution
Stratec's stock price is $21.77.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $361M | $265M | 0.0% | XXX | XXX | XXX | $1.55 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialStratec Valuation Multiples
Stratec trades at 1.2x EV/Revenue multiple, and 7.5x EV/EBITDA.
EV / Revenue (LTM)
Stratec Financial Valuation Multiples
As of April 20, 2026, Stratec has market cap of $265M and EV of $361M.
Equity research analysts estimate Stratec's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Stratec has a P/E ratio of 16.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $265M | XXX | $265M | XXX | XXX | XXX |
| EV (current) | $361M | XXX | $361M | XXX | XXX | XXX |
| EV/Revenue | 1.2x | XXX | 1.2x | XXX | XXX | XXX |
| EV/EBITDA | 7.5x | XXX | 6.5x | XXX | XXX | XXX |
| EV/EBIT | 13.5x | XXX | 10.9x | XXX | XXX | XXX |
| EV/Gross Profit | 4.3x | XXX | 4.0x | XXX | XXX | XXX |
| P/E | 16.1x | XXX | 14.0x | XXX | XXX | XXX |
| EV/FCF | 16.2x | XXX | 9.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Stratec Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Stratec Margins & Growth Rates
Stratec's revenue in the last 12 month grew by 7%.
Stratec's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.0M for the same period.
Stratec's rule of 40 is 24% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Stratec's rule of X is 35% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Stratec Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | (2%) | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Growth | 13% | XXX | (17%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 24% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 35% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 5% | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 9% | XXX | 9% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 4% | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 19% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Stratec Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Stratec | XXX | XXX | XXX | XXX | XXX | XXX |
| 908 Devices | XXX | XXX | XXX | XXX | XXX | XXX |
| Orchestra BioMed | XXX | XXX | XXX | XXX | XXX | XXX |
| Ascom | XXX | XXX | XXX | XXX | XXX | XXX |
| Senseonics Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| Eurobio Scientific | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Stratec M&A Activity
Stratec acquired XXX companies to date.
Last acquisition by Stratec was on XXXXXXXX, XXXXX. Stratec acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Stratec
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialStratec Investment Activity
Stratec invested in XXX companies to date.
Stratec made its latest investment on XXXXXXXX, XXXXX. Stratec invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Stratec
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Stratec
| When was Stratec founded? | Stratec was founded in 1979. |
| Where is Stratec headquartered? | Stratec is headquartered in Germany. |
| How many employees does Stratec have? | As of today, Stratec has over 1K employees. |
| Is Stratec publicly listed? | Yes, Stratec is a public company listed on Frankfurt Stock Exchange. |
| What is the stock symbol of Stratec? | Stratec trades under SBS ticker. |
| When did Stratec go public? | Stratec went public in 1998. |
| Who are competitors of Stratec? | Stratec main competitors are 908 Devices, Orchestra BioMed, Ascom, Senseonics Holdings. |
| What is the current market cap of Stratec? | Stratec's current market cap is $265M. |
| What is the current revenue of Stratec? | Stratec's last 12 months revenue is $304M. |
| What is the current revenue growth of Stratec? | Stratec revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Stratec? | Current revenue multiple of Stratec is 1.2x. |
| Is Stratec profitable? | Yes, Stratec is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Stratec? | Stratec's last 12 months EBITDA is $48M. |
| What is Stratec's EBITDA margin? | Stratec's last 12 months EBITDA margin is 16%. |
| What is the current EV/EBITDA multiple of Stratec? | Current EBITDA multiple of Stratec is 7.5x. |
| What is the current FCF of Stratec? | Stratec's last 12 months FCF is $22M. |
| What is Stratec's FCF margin? | Stratec's last 12 months FCF margin is 7%. |
| What is the current EV/FCF multiple of Stratec? | Current FCF multiple of Stratec is 16.2x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.